Introduction and Objective COVID-19 is an ongoing, global public health crisis for which safe
and effective treatments need to be identified. The benefit-risk balance for the use of …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Nirmatrelvir-ritonavir for COVID-19 | CMAJ Skip to main content Main menu Home Content
Current issue Past issues Early releases Collections Sections Blog Infographics & illustrations …

The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …

(Background) Lopinavir-ritonavir (LPV/RTV) is a human immunodeficiency virus (HIV)
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

CLINICAL QUESTION What is the role of drug interventions in the treatment of patients with
covid-19? NEW RECOMMENDATION The latest version of this WHO living guidance …

In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …

Objectives Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral
agent targeting the 3-chymotrypsin–like cysteine protease enzyme (3C-like protease or …

Objective Provide a timely, rigorous, and continuously updated summary of the evidence on
the role of lopinavir/ritonavir in the treatment of patients with COVID-19. Methods We …